On June 7, 2021, the FDA approved aducanumab to treat patients with Alzheimer’s disease .
For more information about this new treatment, please click here.
The Cleveland Alzheimer’s Disease Research Center (CADRC) is a National Institute on Aging Center which has the goal of increasing the speed of research being done on aging-related brain disorders. A key activity of the CADRC is a multi-site, observational study in which older individuals both with and without dementia will be followed over time. Participants will be asked to undergo bio-specimen collection, imaging procedures, and cognitive testing on an annual basis. This readily-available data will be used to advance national-level future research, including therapeutic trials.
CADRC Investigator News
Lynn Bekris, PhD, Associate Staff at the Cleveland Clinic Genomic Medicine Institute and leader of the CADRC Biomarker Core, has been awarded a three-year, nearly $300,000 grant from the Aging Mind Foundation to study inflammatory factors involved in the early stages of Alzheimer’s disease (AD) in order to better understand the underlying cause of AD and inform novel therapeutic strategies.
Translational Therapeutics Core Leader
“There is a growing body of evidence in the field that Alzheimer’s disease develops much earlier than previously thought, most likely decades before our current ability to clinically diagnose the condition,” said study co-author Andrew A. Pieper.
“Our goal is to provide supportive intervention for those caring for someone with dementia, particularly during these transitional periods of caregiving for persons with dementia,” Zauszniewski said.
OREC Team Member
We have a number of exciting opportunities to learn more and get involved
CADRC is a collaboration between Case Western Reserve University, Cleveland Clinic, University Hospitals and the Louis Stokes Cleveland VA Medical Center
For COVID-19 (The Novel Coronavirus) Information for Caregivers please click here.
Para obtener información sobre COVID-19 (El nuevo coronavirus) para cuidadores, haga clic aquí.